Lower Contrast Dose With Virtual Monoenergetic Imaging Shows Promise After Kidney Cryoablation

Patients who undergo image-guided destruction of small kidney tumors often need repeated contrast-enhanced scans, and each injection of iodinated contrast medium adds a burden to kidneys that may already be struggling. A new feasibility study from a team of interventional radiologists and medical physicists reports that cutting the contrast dose in half during follow-up imaging after percutaneous renal cryoablation did not measurably compromise the key imaging signal, provided the scans were reconstructed with low-energy virtual monoenergetic imaging rather than conventional polychromatic images. The work, published as a short communication in CVIR Oncology, suggests a practical route toward gentler post-ablation surveillance protocols, while its authors are careful to stress that the findings are preliminary and require prospective confirmation.

The research addressed a familiar clinical tension. Reducing contrast medium dose is of particular interest for patients with compromised renal function and for procedures that require repeated imaging over time, because iodinated contrast agents are cleared by the kidneys and repeated exposures can compound the stress on renal tissue. Prior studies had already demonstrated the utility of low-energy virtual monoenergetic imaging for post-ablation assessment and had explored the potential for contrast dose reduction in diagnostic imaging more broadly. What remained missing, the authors noted, was evidence combining the two benefits: using low-energy virtual monoenergetic imaging specifically to allow a reduced contrast dose during image-guided ablation workflows. Their study was designed as a first feasibility look at exactly that combination in the setting of percutaneous renal cryoablation, a minimally invasive technique that destroys tumor tissue by freezing it.

To test the concept, the researchers retrospectively reviewed twenty-four cases and stratified them into two cohorts based on the administered contrast medium dose, using Omnipaque at a concentration of 350 milligrams of iodine per milliliter. The standard-dose cohort received 100 milliliters of contrast medium and comprised twelve patients with a mean age of 70 years, 67 percent of whom were male, and a mean body mass index of 31. The reduced-dose cohort also comprised twelve patients, who received just 50 milliliters of contrast medium; these patients had a mean age of 64 years, 83 percent were male, and their mean body mass index was likewise 31. In both cohorts the contrast medium was injected at a rate of 3.0 milliliters per second, followed by a 50 milliliter saline flush. Images were acquired during two distinct enhancement phases: the corticomedullary phase at 45 seconds and the nephrographic phase at 90 seconds after injection.

The central quantitative comparison focused on the signal difference between the ablation zone and the surrounding renal parenchyma, which is the measurement that determines whether radiologists can confidently distinguish treated tissue from healthy kidney. The team measured this signal contrast using two 10 millimeter diameter regions of interest per case. On conventional images from the standard contrast dose cohort, the signal difference averaged 103 plus or minus 17 Hounsfield units. On the reduced-dose images reconstructed at 55 kiloelectron volts using virtual monoenergetic imaging, the corresponding measurement was 103 plus or minus 23 Hounsfield units. A Wilcoxon rank-sum test found no significant difference between these values, with a p value of 0.88, although the authors explicitly noted that equivalence was not formally tested. In other words, the halved contrast dose paired with 55 keV reconstruction produced a signal contrast that was statistically indistinguishable from the standard approach in this sample, even though the study was not powered to prove true equivalence.

Virtual monoenergetic imaging is a reconstruction technique available on dual-energy and photon-counting capable computed tomography systems. Instead of presenting an image built from the full spectrum of X-ray energies in the beam, it synthesizes what the scan would look like if all photons had a single energy, in this case 55 kiloelectron volts. Because iodine attenuates low-energy X-rays much more strongly than higher-energy X-rays, low-energy virtual monoenergetic images amplify the signal from iodinated contrast within blood vessels and enhancing tissue. This physical property is what allowed the reduced 50 milliliter contrast bolus to generate an ablation zone signal comparable to that produced by the full 100 milliliter dose on conventional images. The study’s figures showed that the 55 keV series boosted ablation zone contrast relative to conventional series in both dose cohorts, with signal contrast plotted across virtual monoenergetic levels from 40 to 70 keV in 5 keV increments and the conventional series shown as a reference line.

Beyond the objective measurements, the investigators ran a structured reader assessment with two interventional radiologists. Each radiologist first completed a calibration phase, reviewing standard-dose conventional images to establish a personal reference for what standard ablation margin visualization should look like. The readers then reviewed the reduced contrast dose conventional series and the reduced-dose 55 keV virtual monoenergetic series. Ablation zone conspicuity was rated on a scale from 0 to 100, anchored at 0 for poor, 50 for standard, and 100 for excellent visualization. Overall image quality was judged on a 5-point Likert scale, where 1 meant conventional images were much better and 5 meant the 55 keV virtual monoenergetic images were much better. The readers also gave a forced-choice yes or no answer on whether each series was clinically acceptable. Importantly, repeat measurements from the two readers were not pooled during the statistical analysis, so each reader’s ratings were treated as separate observations.

The reader results favored the low-energy reconstruction decisively on the subjective measures. For reduced-dose imaging, ablation zone conspicuity was rated substantially higher on the 55 keV virtual monoenergetic series than on the reduced-dose conventional series, with mean scores of 52 plus or minus 11 versus 27 plus or minus 8, a difference that reached statistical significance with a Wilcoxon signed-rank test p value below 0.001. Inter-reader agreement on conspicuity ratings was moderate, with an intraclass correlation coefficient of 0.65 and a 95 percent confidence interval ranging from 0.33 to 0.83; the authors pointed out that this wide interval signals real uncertainty about the precision of that estimate. Overall image quality also favored the 55 keV series, earning a mean Likert score of 4.0 plus or minus 0.2 with 92 percent exact agreement between the two readers. When it came to the binary question of clinical acceptability, the picture was more nuanced: reduced contrast dose with conventional reconstruction was deemed clinically acceptable in 22 of 24 reader assessments, or 92 percent, with 83 percent exact agreement, while the reduced-dose 55 keV virtual monoenergetic series was considered acceptable in 23 of 24 assessments, or 96 percent, with 92 percent exact agreement.

The study also explored what happens when enhancement falls short. In selected cases with suboptimal contrast enhancement, the authors reported that further reduction of the virtual monoenergetic energy level may improve conspicuity. One illustrative case was rated insufficient for post-ablation assessment on the conventional series but clinically acceptable on the 55 keV series. Another case was rated insufficient on both the conventional and the 55 keV series, but when the virtual monoenergetic setting was dropped to 40 keV, the post-ablation assessment improved. These examples hint that the technique offers a tunable dial: when a reduced contrast bolus produces weak enhancement, dropping the reconstructed energy level can recover iodine signal, though the authors present this as an observation from individual cases rather than a systematically validated protocol.

The authors were candid about the limitations that temper these encouraging signals. Generalizability is constrained by the small sample size of twenty-four cases and the two-reader design, and blinding to reconstruction type was not feasible because the visually apparent differences in image appearance made it obvious to readers which series they were viewing. Because the reduced-dose conventional images were already deemed clinically acceptable in most assessments, the authors suggested that the real benefit of 55 keV virtual monoenergetic imaging may lie primarily in improved conspicuity and reader confidence rather than in a dramatic shift in acceptability rates. Patient-level variables and clinical outcome data, including comorbidities, tumor characteristics, laterality, serum creatinine, and estimated glomerular filtration rate, were not uniformly available and therefore could not be analyzed. The cohorts also differed in age and sex distribution, a potential source of confounding that the retrospective design could not control. Prospective studies, the team concluded, are needed to evaluate the safety, generalizability, and non-inferiority of reduced-dose protocols before they can be broadly implemented.

The takeaway for the field is a proof of concept rather than a practice change. Within this retrospective, two-cohort feasibility framework, halving the contrast medium dose from 100 to 50 milliliters and reconstructing follow-up scans at 55 keV yielded ablation zone-to-renal parenchyma signal contrast that was not significantly different from the standard-dose conventional approach, while reader-rated conspicuity and overall image quality clearly favored the low-energy reconstruction within the reduced-dose cohort. For patients with impaired renal function who face repeated post-ablation scans, and for the radiologists who monitor those scans for signs of residual or recurrent tumor, the results support moving this combination of reduced contrast dose and low-energy virtual monoenergetic imaging into properly designed prospective trials, where non-inferiority can be formally established and the technique’s real-world value can be confirmed.

Subject of Research: Reducing intravenous contrast dose with low-energy virtual monoenergetic imaging for post-ablation kidney imaging

Article Title: Intravenous contrast dose reduction with low-energy virtual monoenergetic imaging after renal cryoablation

Article References: Huber, N. R., Hibbert, R., Dobrolinska, M. M., Musa, J., Atwell, T. D., Favazza, C. P., & Parvinian, A. (2026). Intravenous contrast dose reduction with low-energy virtual monoenergetic imaging after renal cryoablation. CVIR Oncology, 2(1), Article 36. https://doi.org/10.1007/s44343-026-00068-w

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00068-w

Keywords: renal cryoablation, contrast dose reduction, virtual monoenergetic imaging, dual-energy CT, ablation zone conspicuity, interventional radiology, image quality, kidney cancer, photon-counting CT, feasibility study, Intravenous, contrast